NCT06193889 - KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 28, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2028

Conditions

Myasthenia GravisGeneralized Myasthenia Gravis

Interventions

DRUG

Standard of Care Treatment

Standard of Care Medications Optional Crossover to receive KYV-101 treatment

DRUG

Standard lymphodepletion regimen

BIOLOGICAL

KYV-101

Anti-CD19 CAR-T cell therapy

Trial Locations (11)

15212

RECRUITING

Allegheny General Hospital, Pittsburgh

33149

RECRUITING

University of Miami, Miami

84107

RECRUITING

Intermountain Medical Center, Murray

92868

RECRUITING

University of California, Irvine, Orange

94305

RECRUITING

Stanford University Medical Center, Palo Alto

Unknown

RECRUITING

Charite- Universitätsklinikum Berlin, Berlin

RECRUITING

Universitätsklinikum der Ruhr-Universität Bochum, Bochum

RECRUITING

Universitätsklinikum Hamburg-Eppendorf, Hamburg

RECRUITING

Medizinische Hochscule Hannover, Hanover

RECRUITING

Friedrich-Schiller-Universität Jena, Jena

RECRUITING

Universitätsklinik Magdeburg, Magdeburg